EFLDO sensitizes liver cancer cells to TNFSF10‑induced apoptosis in a p53‑dependent manner

Qu,Yanbo; Liao,Zhixin; Wang,Xinzhu; Zhang,Jing; Liu,Chao

doi:10.3892/mmr.2019.10046

EFLDO sensitizes liver cancer cells to TNFSF10‑induced apoptosis in a p53‑dependent manner

Authors:
- Yanbo Qu
- Zhixin Liao
- Xinzhu Wang
- Jing Zhang
- Chao Liu
View Affiliations

Affiliations: Department of Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Southeast University, Nanjing, Jiangsu 211189, P.R. China, Key Laboratory of Agro‑Products Processing Technology of Shandong Province, Institute of Agro‑Food Science and Technology, Shandong Academy of Agricultural Sciences, Jinan, Shandong 250100, P.R. China
Published online on: March 15, 2019 https://doi.org/10.3892/mmr.2019.10046
Pages: 3799-3806

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ent‑3α‑formylabieta‑8(14),13(15)‑dien‑16,12β‑olide (EFLDO) is a compound extracted from Euphorbia lunulata Bge exhibiting anti‑proliferative activity in vitro. In the present study, EFLDO was identified to sensitize HepG2 cells to tumor necrosis factor (TNF) superfamily member 10 (TNFSF10)‑induced apoptosis. Liver cancer cells were resistant to TNFSF10; however, EFLDO increased TNFSF10‑induced cancer cell viability inhibition and cell apoptosis induction as assessed by MTT assay and Annexin V‑fluorescein isothiocyanate (FITC)/propidium iodide assay, respectively. The western blotting results suggested that treatment with EFLDO increased TNFSF10‑induced upregulation of the protein expression levels of pro‑apoptotic proteins, including BCL2 associated agonist of cell death, BCL2 associated X, apoptosis regulator, caspase‑3 (CASP3) and CASP8. Furthermore, treatment with EFLDO increased TNFSF10‑mediated downregulation of the protein expression level of the anti‑apoptotic protein BCL2 apoptosis regulator. Notably, the increase in the activity of CASP3 was consistent with the western blotting results. Treatment with EFLDO sensitized liver cancer cells to TNFSF10, and apoptosis was induced via the upregulation of TNF receptor superfamily member 10a (TNFRSF10A) and TNFRSF10B in a tumor protein p53 (p53)‑dependent manner, as detected by reverse transcription‑quantitative polymerase chain reaction and western blot analyses. In addition, p53 was identified to be necessary for EFLDO‑induced sensitivity to TNFSF10, as assessed by western blotting and Annexin V‑FITC assay. Collectively, the present results suggested a novel mechanism underlying EFLDO function in liver cancer. Treatment with EFLDO was able to increase the antitumor effect of TNFSF10 in liver cancer cells in a p53‑dependent manner.

View Figures

View References

1	Takada Y, Tohyama T and Watanabe J: Biological markers of hepatocellular carcinoma for use as selection criteria in liver transplantation. J Hepatobiliary Pancreat Sci. 22:279–286. 2015. View Article : Google Scholar : PubMed/NCBI
2	Ling D, Xia H, Park W, Hackett MJ, Song C, Na K, Hui KM and Hyeon T: pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma. ACS Nano. 8:8027–8039. 2014. View Article : Google Scholar : PubMed/NCBI
3	Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS, Shackelford KA, Steiner C, Heuton KR, Gonzalez-Medina D, Barber R, Huynh C, Dicker D, et al: Global, regional, and national levels and causes of maternal mortality during 1990–2013: A systematic analysis for the Global burden of disease study 2013. Lancet. 384:980–1004. 2014. View Article : Google Scholar : PubMed/NCBI
4	Alsaied OA, Sangwan V, Banerjee S, Krosch TC, Chugh R, Saluja A, Vickers SM and Jensen EH: Sorafenib and triptolide as combination therapy for hepatocellular carcinoma. Surgery. 156:270–279. 2014. View Article : Google Scholar : PubMed/NCBI
5	Chen W, Zhang Y, Li Y, Zhang J, Zhang T, Fu B, Zhang Q and Jiang N: Constitutive expression of Wnt/β-catenin target genes promotes proliferation and invasion of liver cancer stem cells. Mol Med Rep. 13:3466–3474. 2016. View Article : Google Scholar : PubMed/NCBI
6	He S, Chen Y, Chen XP, Zhang WG, Wang HP, Zhao YZ and Wang SF: Antitumor effects of soluble TRAIL in human hepatocellular carcinoma. J Huazhong Univ Sci Technolog Med Sci. 25:51–54. 2005. View Article : Google Scholar : PubMed/NCBI
7	He SQ, Rehman H, Gong MG, Zhao YZ, Huang ZY, Li CH, Zhang WG and Chen XP: Inhibiting survivin expression enhances TRAIL-induced tumoricidal activity in human hepatocellular carcinoma via cell cycle arrest. Cancer Biol Ther. 6:1247–1257. 2007. View Article : Google Scholar : PubMed/NCBI
8	Zhang Y, Ma H, Zhang J, Liu S, Liu Y and Zheng D: AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sci. 82:1154–1161. 2008. View Article : Google Scholar : PubMed/NCBI
9	Zhang Y, Qu ZH, Cui M, Guo C, Zhang XM, Ma CH and Sun WS: Combined endostatin and TRAIL gene transfer suppresses human hepatocellular carcinoma growth and angiogenesis in nude mice. Cancer Biol Ther. 8:466–473. 2009. View Article : Google Scholar : PubMed/NCBI
10	Zhang B, Shan H, Li D, Zhu KS, Jiang ZB and Huang MS: Cisplatin sensitizes human hepatocellular carcinoma cells, but not hepatocytes and mesenchymal stem cells, to TRAIL within a therapeutic window partially depending on the upregulation of DR5. Oncol Rep. 25:461–468. 2011.PubMed/NCBI
11	Lee JY, Jung KH, Morgan MJ, Kang YR, Lee HS, Koo GB, Hong SS, Kwon SW and Kim YS: Sensitization of TRAIL-induced cell death by 20(S)-ginsenoside Rg3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells. Mol Cancer Ther. 12:274–285. 2013. View Article : Google Scholar : PubMed/NCBI
12	Okano H, Shiraki K, Inoue H, Kawakita T, Yamanaka T, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Fujikawa K, et al: Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest. 83:1033–1043. 2003. View Article : Google Scholar : PubMed/NCBI
13	Ganten TM, Haas TL, Sykoraet J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, et al: Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ. 11 (Suppl 1):S86–S96. 2004. View Article : Google Scholar : PubMed/NCBI
14	Su CL, Wu CJ, Chen FN, Wang BJ, Sheu SR and Won SJ: Supernatant of bacterial fermented soybean induces apoptosis of human hepatocellular carcinoma Hep 3B cells via activation of caspase 8 and mitochondria. Food Chem Toxicol. 45:303–314. 2007. View Article : Google Scholar : PubMed/NCBI
15	Youness ER, El Nemr M, Oraby FS, Ahmed NM, Moghni MA, Aly HF and Ahmed HH: Evaluation of apoptotic marker Bcl2, CD4+, human hepatocyte growth factor and metalloproteinase-9 as tumor markers for patients with hepatocellular carcinoma. Indian J Clin Biochem. 29:351–356. 2014. View Article : Google Scholar : PubMed/NCBI
16	Zhang L and Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12:228–237. 2005. View Article : Google Scholar : PubMed/NCBI
17	Liu C, Liao ZX, Liu SJ, Qu YB and Wang HS: Two new derivatives from Euphorbia lunulata bge and their anti-proliferation activities. Fitoterapia. 96:33–38. 2014. View Article : Google Scholar : PubMed/NCBI
18	Qu YB, Liao ZX, Liu C, Wang XZ and Zhang J: EFLDO induces apoptosis in hepatic cancer cells by caspase activation in vitro and suppresses tumor growth in vivo. Biomed Pharmacother. 100:407–416. 2018. View Article : Google Scholar : PubMed/NCBI
19	López-Terrada D, Cheung SW, Finegold MJ and Knowles BB: HepG2 is a hepatoblastoma-derived cell line. Hum Pathol. 40:1512–1515. 2009. View Article : Google Scholar
20	Twentyman P and Luscombe M: A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer. 56:279–285. 1987. View Article : Google Scholar : PubMed/NCBI
21	Fossati S, Ghiso J and Rostagno A: TRAIL death receptors DR4 and DR5 mediate cerebral microvascular endothelial cell apoptosis induced by oligomeric Alzheimer's Aβ. Cell Death Dis. 3:e3212012. View Article : Google Scholar : PubMed/NCBI
22	Tomasetti M, Andera L, Alleva R, Borghi B, Neuzil J and Procopio A: Alpha-tocopheryl succinate induces DR4 and DR5 expression by a p53-dependent route: Implication for sensitisation of resistant cancer cells to TRAIL apoptosis. FEBS Lett. 580:1925–1931. 2006. View Article : Google Scholar : PubMed/NCBI
23	Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al: Phenotypic character-ization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
24	Ino Y, Gotoh M, Sakamoto M, Tsukagoshi K and Hirohashi S: Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis. Proc Natl Acad Sci USA. 99:365–370. 2002. View Article : Google Scholar : PubMed/NCBI
25	Nam JS, Hirohashi S and Wakefield LM: Dysadherin: A new player in cancer progression. Cancer Lett. 255:161–169. 2007. View Article : Google Scholar : PubMed/NCBI
26	El-Shemi AG, Ashshi AM, Na Y, Li YM, Al-Allaf FA, Oh E, Jung BK and Yun CO: Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model. J Exp Clin Cancer Res. 35:742016. View Article : Google Scholar : PubMed/NCBI
27	Chiu CT, Yeh TS, Hsu JC and Chen M: Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocellular carcinoma. Dig Dis Sci. 48:670–676. 2003. View Article : Google Scholar : PubMed/NCBI
28	Franklin DA, He Y, Leslie PL, Tikunov AP, Fenger N, Macdonal JM and Zhang Y: p53 coordinates DNA repair with nucleotide synthesis by suppressing PFKFB3 expression and promoting the pentose phosphate pathway. Sci Rep. 6:380672016. View Article : Google Scholar : PubMed/NCBI
29	Romano FJ, Rossetti S, Conteduca V, Schepisi G, Cavaliere C, Di Franco R, La Mantia E, Castaldo L, Nocerino F, Ametrano G, et al: Role of DNA repair machinery and p53 in the testicular germ cell cancer: A review. Oncotarget. 7:85641–85649. 2016. View Article : Google Scholar : PubMed/NCBI